The December conference of the American Society of Hematology (ASH, Washington) in San Diego was marked by the continued emphasis on diagnostic technologies as the core of a highly clinical and biological meeting. Few meetings across the clinical spectrum address biology, biochemistry, and biomarkers in a way that annual meetings at ASH in hematology, and at the American Society of Clinical Oncology (ASCO, Alexandria, Virginia) in solid oncology, tend to.